AxoGen, Inc. (NASDAQ:AXGN) is Perkins Capital Management Inc.’s 5th Largest Position

Perkins Capital Management Inc. lessened its holdings in AxoGen, Inc. (NASDAQ:AXGN) by 2.1% during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 283,399 shares of the medical equipment provider’s stock after selling 5,950 shares during the period. AxoGen makes up approximately 3.7% of Perkins Capital Management Inc.’s portfolio, making the stock its 5th biggest holding. Perkins Capital Management Inc. owned 0.65% of AxoGen worth $3,973,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the business. nVerses Capital LLC bought a new stake in AxoGen in the third quarter worth about $56,000. Koss Olinger Consulting LLC bought a new stake in shares of AxoGen in the 2nd quarter worth approximately $75,000. Lazard Asset Management LLC lifted its stake in AxoGen by 30.1% in the first quarter. Lazard Asset Management LLC now owns 11,539 shares of the medical equipment provider’s stock valued at $93,000 after purchasing an additional 2,671 shares during the last quarter. SG Americas Securities LLC bought a new position in AxoGen during the third quarter valued at $227,000. Finally, Sentry Investment Management LLC increased its position in AxoGen by 9.3% in the third quarter. Sentry Investment Management LLC now owns 17,368 shares of the medical equipment provider’s stock worth $243,000 after buying an additional 1,483 shares during the last quarter. 80.29% of the stock is owned by institutional investors.

AxoGen Price Performance

AxoGen stock opened at $15.33 on Thursday. The company has a debt-to-equity ratio of 0.70, a current ratio of 3.51 and a quick ratio of 2.32. AxoGen, Inc. has a one year low of $4.16 and a one year high of $15.90. The firm has a market capitalization of $671.91 million, a P/E ratio of -40.34 and a beta of 1.13. The business has a fifty day moving average price of $13.81 and a 200-day moving average price of $10.05.

AxoGen (NASDAQ:AXGN) last issued its earnings results on Thursday, August 8th. The medical equipment provider reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.10. AxoGen had a negative return on equity of 17.30% and a negative net margin of 9.53%. The business had revenue of $47.91 million during the quarter, compared to the consensus estimate of $43.27 million. As a group, equities research analysts forecast that AxoGen, Inc. will post -0.33 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on AXGN. StockNews.com raised AxoGen from a “hold” rating to a “buy” rating in a research report on Tuesday, October 15th. JMP Securities boosted their price objective on AxoGen from $17.00 to $20.00 and gave the company a “market outperform” rating in a research note on Friday, August 9th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, AxoGen has a consensus rating of “Buy” and a consensus target price of $15.00.

AxoGen Company Profile

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.